In 95% of patients with PV and 60% of those with ET, a single somatically acquired mutation is found in the gene encoding JAK2 [2,3,4,5], resulting in the V617F substitution at the protein level that dysregulates the kinase activity and drives the ligand-independent activation of receptor signaling. This evidence concerns the gene JAK2 and essential thrombocythemia.